Table 3.
Pharmacodynamic parameters following a MMTT on SD1 and SD2 adjusted for gestational-age-dependent changes in adherent subjects with GDM who completed the study.
| Parameter | COMBO (n = 32) | GLY (n = 32) | MET (n = 25) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| SD1 | SD2 | Δ | SD1 | SD2 | Δ | SD1 | SD2 | Δ | |
| SI (10−4 min−1 μU−1 mL) | 3 ± 2 (2 to 3) | 4 ± 2 (3 to 4) | 0.9 ± 2 (0.1 to 2) (p=0.03*) | 3 ± 3 (2 to 4) | 3 ± 2 (2 to 3) | −0.3 ± 2 (−1 to 0.6) (p=0.5) | 3 ± 2 (2 to 4) | 4 ± 2 (4 to 5) | 2 ± 2 (0.5 to 3) (p=0.005**) |
| Φtotal (10−9 min−1) | 100 ± 60 (81 to 130) | 140 ± 80 (110 to 170) | 40 ± 80 (20 to 70) (p=0.004**) | 80 ± 30 (70 to 90) | 100 ± 40 (80 to 100) | 10 ± 50 (−6 to 30) (p=0.2) | 100 ± 50 (83 to 120) | 130 ± 70 (99 to 160) | 30 ± 60 (1 to 50) (p=0.04*) |
| Φstatic (10−9 min−1) | 90 ± 60 (70 to 100) | 130 ± 70 (100 to 160) | 40 ± 70 (20 to 70) (p=0.002**) | 70 ± 30 (70 to 80) | 90 ± 40 (80 to 100) | 10 ± 50 (−3 to 30) (p=0.09) | 90 ± 40 (70 to 100) | 120 ± 70 (87 to 150) | 30 ± 60 (1 to 50) (p=0.04*) |
| Φdynamic (10−9) | 2,000 ± 1,000 (2,000 to 2,000) | 2,000 ± 1,000 (1,000 to 2,000) | −400 ± 1,000 (−800 to 60) (p=0.09) | 1,400 ± 1,000 (1,100 to 1,800) | 800 ± 500 (600 to 900) | −600 ± 800 (−900 to −300) (p=1e-04***) | 2,000 ± 1,000 (1,000 to 2,000) | 2,000 ± 1,000 (2,000 to 3,000) | 100 ± 1,000 (−300 to 600) (p=0.5) |
| Φbaseline (10−9 min−1) | 13 ± 6 (11 to 15) | 13 ± 10 (9 to 16) | −0.5 ± 7 (−3 to 2) (p=0.7) | 10 ± 6 (8 to 12) | 10 ± 10 (9 to 20) | 3 ± 8 (0.3 to 6) (p=0.03*) | 11 ± 5 (9.3 to 14) | 9 ± 6 (6 to 10) | −3 ± 4 (−4 to −0.9) (p=0.004**) |
| DI (10−13 min−2 μU−1 mL) | 300 ± 400 (200 to 400) | 500 ± 400 (400 to 700) | 300 ± 300 (100 to 400) (p=2e-04***) | 200 ± 200 (200 to 300) | 300 ± 300 (200 to 500) | 100 ± 300 (5 to 200) (p=0.04*) | 300 ± 300 (200 to 400) | 600 ± 400 (500 to 800) | 300 ± 500 (100 to 500) (p=0.003**) |
| Peak glucose (mg/dL) | 160 ± 30 (150 to 170) | 150 ± 20 (140 to 160) | −9 ± 30 (−20 to 0.3) (p=0.06) | 170 ± 20 (160 to 180) | 170 ± 30 (160 to 180) | 2 ± 30 (−7 to 10) (p=0.7) | 150 ± 20 (140 to 160) | 140 ± 20 (130 to 140) | −10 ± 20 (−20 to −4) (p=0.006**) |
COMBO = glyburide/metformin combination therapy group; DI = disposition index (SI • Φtotal); GDM = gestational diabetes mellitus; GLY = glyburide monotherapy group; HP = healthy pregnant; MET = metformin monotherapy group; MMTT = mixed-meal tolerance test; Φ = β-cell responsivity; SD = standard deviation; SI = insulin sensitivity; Δ = average change between study day 1 and study day 2. Results reported as mean ± SD (95% confidence interval).